CollabRx today announced a deal with Sengenics to incorporate each other’s products into molecular diagnostics tests and reports aimed at cancer.
Under the terms of the agreement, Sengenics will integrate CollabRx’s interpretive content resources into its cancer exome sequencing tests and reports. The combined products are being designed “to seamlessly pair test results with clinically actionable and dynamically updated knowledge on the clinical impact of specific tumor genetic profiles and associated therapeutic strategies, such as drugs and clinical trials,” CollabRx said.
The San Francisco-based data analytics firm added that it will provide content in a software-as-a-service-based business model.
The deal, CollabRx said, extends its presence into three continents: North America, Europe, and Asia. Financial and other terms of the agreement were not disclosed.
Today’s announcement follows a test and medical information development partnership between CollabRx and OncoDNA that was announced last week.
Based in Kuala Lumpur, Malaysia, Sengenics offers genomics- and proteomics-based diagnostics.
“Our joint solution’s ability to provide insights from CollabRx’s clinical practitioner network represents critical and timely value to physicians when they are interpreting test results,” Arif Anwar, executive director of Sengenics, said in a statement.